BR112022011276A2 - Biomolécula para tratamento de patologias da córnea - Google Patents

Biomolécula para tratamento de patologias da córnea

Info

Publication number
BR112022011276A2
BR112022011276A2 BR112022011276A BR112022011276A BR112022011276A2 BR 112022011276 A2 BR112022011276 A2 BR 112022011276A2 BR 112022011276 A BR112022011276 A BR 112022011276A BR 112022011276 A BR112022011276 A BR 112022011276A BR 112022011276 A2 BR112022011276 A2 BR 112022011276A2
Authority
BR
Brazil
Prior art keywords
biomolecule
treatment
corneal
pathologies
corneal pathologies
Prior art date
Application number
BR112022011276A
Other languages
English (en)
Portuguese (pt)
Inventor
Bazan Haydee
G Bazan Nicolas
L Pham Thang
Jun Bokkyoo
A Petasis Nicos
Original Assignee
Univ Louisiana State
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Univ Southern California filed Critical Univ Louisiana State
Publication of BR112022011276A2 publication Critical patent/BR112022011276A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112022011276A 2019-12-09 2020-12-09 Biomolécula para tratamento de patologias da córnea BR112022011276A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962945580P 2019-12-09 2019-12-09
PCT/US2020/064042 WO2021119146A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Publications (1)

Publication Number Publication Date
BR112022011276A2 true BR112022011276A2 (pt) 2022-09-06

Family

ID=76330542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011276A BR112022011276A2 (pt) 2019-12-09 2020-12-09 Biomolécula para tratamento de patologias da córnea

Country Status (8)

Country Link
US (1) US20230019568A1 (https=)
EP (1) EP4072578A4 (https=)
JP (1) JP2023504205A (https=)
CN (1) CN115038434A (https=)
AU (1) AU2020402031A1 (https=)
BR (1) BR112022011276A2 (https=)
CA (1) CA3161233A1 (https=)
WO (1) WO2021119146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311554A1 (en) * 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018333A2 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
HK1211867A1 (en) * 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
US20240041813A1 (en) * 2020-09-10 2024-02-08 Boards of Supervisors of Louisiana State University and Agricultural and Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Also Published As

Publication number Publication date
WO2021119146A1 (en) 2021-06-17
CN115038434A (zh) 2022-09-09
AU2020402031A1 (en) 2022-06-30
EP4072578A1 (en) 2022-10-19
JP2023504205A (ja) 2023-02-01
EP4072578A4 (en) 2024-01-10
US20230019568A1 (en) 2023-01-19
CA3161233A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
GEP20217316B (en) Aromatic sulfonamide derivatives
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
EA202191519A1 (ru) Модуляторы trex1
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA202092748A1 (ru) Модуляторы экспрессии apol1
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
BR112022003768A2 (pt) Compostos inibidores de perk
WO2020021480A3 (en) Compositions and methods for treating the eye